CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma
Open Access
- 19 October 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186284
Abstract
Among patients who underwent primary surgery for non-small cell lung cancer (NSCLC), recurrent disease is frequent and cannot be accurately predicted solely from TNM stage and histopathological features. The aim of this study was to examine the association of tumor markers in pre-operative serum with recurrent disease. Blood samples were collected prior to lung cancer surgery from 107 patients with stage I-III lung adenocarcinoma surgically treated at Lund University hospital, Lund, Sweden, between 2005 and 2011. The serum tumor markers Carcinoembryonic antigen (CEA), Neuron-specific enolase (NSE), Cancer antigen 125 (CA 125), Human epididymis protein 4 (HE4) and Carbohydrate antigen (CA 19–9) were analyzed retrospectively and clinical follow-up data were collected from patient charts. Forty (37%) patients were diagnosed with recurrent disease. Sixty-eight (64%) patients had at least one elevated tumor marker prior to surgery. In analysis of disease-free survival (DFS), CA 125 and/or CA 19–9 were significantly associated with recurrent disease adjusted to stage and adjuvant treatment (hazard ratio 2.8, 95% confidence interval 1.4–5.7, p = 0.006). High pre-operative serum CA 19–9 and/or CA 125 might indicate an increased incidence of recurrent disease in resectable lung adenocarcinomas.Keywords
Funding Information
- Swedish Cancer Society
- Mrs Berta Kamprad Foundation
- Gustav V:s Jubilee Foundation, and governmental funding (ALF)
This publication has 25 references indexed in Scilit:
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Serum markers in small cell lung cancer: Opportunities for improvementBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC PatientsInternational Journal of Molecular Sciences, 2013
- Diagnostic Role of Tumour Markers CEA, CA15-3, CA19-9 and CA125 in Lung CancerIndian Journal of Clinical Biochemistry, 2012
- Serum HE4 as a diagnostic and prognostic marker for lung cancerTumor Biology, 2012
- Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)Clinical Lung Cancer, 2011
- Local recurrence after surgery for early stage lung cancerCancer, 2009
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- Comprehensive analysis of HE4 expression in normal and malignant human tissuesLaboratory Investigation, 2006
- Clinical value of p53, c‐erbB‐2, CEA and CA125 regarding relapse, metastasis and death in resectable non‐small cell lung cancerInternational Journal of Cancer, 2003